Zhejiang Medicine Co (SHSE:600216) Other Stockholders Equity: ¥3,754 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600216 Zhejiang Medicine Co Ltd SHSE:600216
81 GF Score
Price ¥12.09
GF Value ¥13.83
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Zhejiang Medicine Co Other Stockholders Equity?

Zhejiang Medicine Co SHSE:600216 -3.97% 81 Other Stockholders Equity is ¥3,754 Mil as of Mar. 2026. GuruFocus rates SHSE:600216 with a GF Score™ of 81/100 and a GF Value™ of ¥13.83 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Zhejiang Medicine Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ¥3,754 Mil.

Zhejiang Medicine Co's quarterly Other Stockholders Equity declined from Sep. 2025 (¥3,779 Mil) to Dec. 2025 (¥2,813 Mil) but then increased from Dec. 2025 (¥2,813 Mil) to Mar. 2026 (¥3,754 Mil).

Zhejiang Medicine Co's annual Other Stockholders Equity increased from Dec. 2023 (¥2,576 Mil) to Dec. 2024 (¥2,696 Mil) and increased from Dec. 2024 (¥2,696 Mil) to Dec. 2025 (¥2,813 Mil).

Zhejiang Medicine Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Zhejiang Medicine Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Medicine Co Other Stockholders Equity Chart

Zhejiang Medicine Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,122.10 2,459.42 2,575.53 2,696.09 2,812.81

Zhejiang Medicine Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,763.86 2,725.88 3,779.09 2,812.81 3,753.75
SHSE:600216
81GF Score
Zhejiang Medicine Co Ltd SHSE:600216
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Medicine Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ¥3,754 Mil mean?
Zhejiang Medicine Co (SHSE:600216) has a Other Stockholders Equity of ¥3,754 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Zhejiang Medicine Co and its competitors.
Is Zhejiang Medicine Co's Other Stockholders Equity too high?
Zhejiang Medicine Co's current Other Stockholders Equity is ¥3,754 Mil. Overall, Zhejiang Medicine Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Medicine Co's Other Stockholders Equity compare to ZTS and UTHR?
Zhejiang Medicine Co's Other Stockholders Equity of ¥3,754 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Zhejiang Medicine Co and its competitors. Zhejiang Medicine Co's current Other Stockholders Equity is ¥3,754 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Medicine Co (SHSE:600216) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥13.83, compared to a current price of ¥12.09 — trading 12.6% below its estimated fair value. The current Other Stockholders Equity is ¥3,754 Mil. Zhejiang Medicine Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Zhejiang Medicine Co (SHSE:600216), the current Other Stockholders Equity is ¥3,754 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Medicine Co (SHSE:600216) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Medicine Co stock appears to be undervalued. The current stock price of ¥12.09 is trading 12.6% below its estimated GF Value™ of ¥13.83. GuruFocus considers Zhejiang Medicine Co to be Modestly Undervalued.

Key valuation signals for SHSE:600216:

  • Other Stockholders Equity: ¥3,754 Mil
  • GF Value™: ¥13.83 vs. price of ¥12.09 (12.6% below fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Medicine Co Business Description

Address Comprehensive Building, No. 398 Mahuan Road, 3rd Floor, Building A, Binhai New City, Shaoxing, CHN, 312366
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
81GF Score

Get the complete analysis for SHSE:600216

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.09
Price
¥13.83
GF Value